湘A1号颗粒治疗脾虚湿盛型艾滋病临床观察与机制研究

发布时间：2018-07-09 10:20

本文选题：艾滋病 + 脾虚湿盛　；参考：《中华中医药杂志》2017年09期

【摘要】：目的:观察湘A1号颗粒治疗艾滋病的临床疗效及安全性,探讨湘A1号颗粒治疗艾滋病的相关机制。方法:采用双盲双模拟设计,将60例艾滋病脾虚湿盛型患者随机分为3组,每组20例。湘A1号组予湘A1号颗粒加抗病毒药物安慰剂;抗病毒组予抗病毒药物加湘A1号颗粒安慰剂;联合组予湘A1号颗粒加抗病毒药物;连续治疗6个月。治疗结束后通过症状体征积分、病毒载量、T细胞亚群进行疗效分析。结果:3组均能有效改善症状体征、提高生活质量(P0.05),湘A1号组与抗病毒组无显著差异,联合组优于湘A1号组和抗病毒组(P0.05);联合组与抗病毒组治疗前后病毒载量计数下降明显(P0.01),且抗病毒作用优于湘A1号组(P0.01);湘A1号组和联合组患者CD45RA+、CD45RA+CD3+、CD45RA+CD28+、CD45RA+CD4+、CD45RA+CD25+百分率及CD4/CD8比值显著上升(P0.01),抗病毒组CD45RA+、CD45RA+CD3+、CD45RA+CD4+百分率及CD4/CD8比值显著上升(P0.01),湘A1号组和联合组治疗后CD45RA+、CD45RA+CD3+、CD45RA+CD28+、CD45RA+CD4+、CD45RA+CD25+百分率与抗病毒组治疗后比较差异有统计学意义(P0.01,P0.05)。结论:湘A1号颗粒能缓解艾滋病脾虚湿盛型患者的症状体征、提高生活质量,湘A1颗粒与抗病毒疗法联用有协同作用;湘A1号颗粒抗病毒作用不明显,但具有明显免疫重建作用。
[Abstract]:Objective: to observe the clinical efficacy and safety of XiangA1 granule in the treatment of AIDS, and to explore the mechanism of XiangA1 granule in the treatment of AIDS. Methods: 60 AIDS patients with spleen deficiency and dampness were randomly divided into 3 groups with 20 cases in each group. Group A 1 was treated with placebo, group A 1 was treated with anti viral drug and group A 1 was treated with anti viral drug for 6 months. After treatment, the therapeutic effect was analyzed by symptom and sign score and viral load T cell subsets. Results all the three groups were able to improve the symptoms and signs and improve the quality of life (P0.05). There was no significant difference between the Xiang A1 group and the antiviral group. The combined group was superior to the XiangA1 group and the antiviral group (P0.05), the viral load in the combined group and the antiviral group decreased significantly before and after treatment (P0.01), and the antiviral effect was better than that in the XiangA1 group (P0.01); the patients in the XiangA1 group and the combined group were treated with CD45RA, CD45RA, CD28, CD45RA, CD4, CD45RA, CD25. The percentage of CD45RA and the ratio of CD4 / CD8 increased significantly (P0.01), the percentage of CD45RA CD3 CD45RA CD4 and CD4 / CD8 increased significantly in antiviral group (P0.01). After treatment, the percentage of CD45RA, CD45RA, CD28, CD45RA, CD4, CD45RA and CD25 in group A 1 and group A were significantly higher than those in group B (P 0.01 P 0.05). Conclusion: XiangA1 granule can alleviate the symptoms and signs of patients with spleen deficiency and dampness and improve the quality of life. XiangA1 granule has synergistic effect with antiviral therapy, but XiangA1 granule has no obvious antiviral effect. But it has obvious immune reconstruction effect.
【作者单位】：湖南中医药大学第二附属医院;湖南中医药大学;衡阳市第三人民医院;湖南省新开铺强制隔离戒毒所医院;
【基金】：湖南中医药大学感染性疾病中医药防治研究团队基金计划项目(No.Crxjb-12) 湖南省教育厅中医外科学重点学科专项基金资助湖南省科技厅课题(No.2013SK3097)~~
【分类号】：R512.91

【相似文献】